Analyst Downgrades – NASDAQ:JNCE – Jounce Therapeutics (NASDAQ:JNCE) Stock Gets Downgraded By Wells Fargo from Outperform ➝ Market Perform to

Analyst Ratings For NASDAQ:JNCE – Jounce Therapeutics (NASDAQ:JNCE)

Today, NASDAQ:JNCE – Jounce Therapeutics (NASDAQ:JNCE) stock was downgraded by Wells Fargo from Outperform ➝ Market Perform to with a price target of $37.00 ➝ $13.00.

Some recent analyst ratings include

  • 5/17/2018-Wells Fargo was Downgraded by analysts at Wells Fargo from a “Outperform ➝ Market Perform” rating to a “” rating. They now have a $37.00 ➝ $13.00 price target on the stock.
  • 6/9/2017-Cowen Reiterated Rating of Buy.


  • On 3/15/2018 Barbara Gayle Duncan, Director, sold 2,000 with an average share price of $28.11 per share and the total transaction amounting to $56,220.00.
  • On 3/8/2018 Elizabeth Trehu, Insider, sold 4,545 with an average share price of $25.06 per share and the total transaction amounting to $113,897.70.
  • On 3/8/2018 Kimberlee C Drapkin, CFO, sold 5,267 with an average share price of $25.01 per share and the total transaction amounting to $131,727.67.
  • On 3/8/2018 Richard /Ca/ Murray, CEO, sold 16,334 with an average share price of $25.10 per share and the total transaction amounting to $409,983.40.
  • On 3/5/2018 Elizabeth Trehu, Insider, sold 4,545 with an average share price of $21.50 per share and the total transaction amounting to $97,717.50.
  • On 3/5/2018 Kimberlee C Drapkin, CFO, sold 5,267 with an average share price of $21.42 per share and the total transaction amounting to $112,819.14.
  • On 3/5/2018 Richard /Ca/ Murray, CEO, sold 16,334 with an average share price of $21.43 per share and the total transaction amounting to $350,037.62.

Recent Trading Activity for NASDAQ:JNCE – Jounce Therapeutics (NASDAQ:JNCE)
Shares of NASDAQ:JNCE – Jounce Therapeutics closed the previous trading session at 12.31 down -5.36 30.33% with 13.0 shares trading hands.

An ad to help with our costs